Patient Experience Placemat
Key information about hypothyroidism and the Synthroid Delivers Program.
DownloadMaterials to help you support patients with hypothyroidism who are enrolled in the Synthroid Delivers Program.
Office Allies provides training for healthcare providers and their staff about the Synthroid Delivers Program.
Utilize these materials to educate your office on hypothyroidism. When Synthroid is chosen for treatment, you can also reference these resources to learn more about the brand and the Synthroid Delivers Program, which helps patients consistently get the medication prescribed by their doctor.
For patients diagnosed with hypothyroidism and prescribed Synthroid, printable resources are available with information on hypothyroidism, the brand, and the Synthroid Delivers Program.
Synthroid Delivers Patient Brochure
Synthroid Delivers Program details, all in one place.
How to take Synthroid
A helpful guide to setting expectations for how to take Synthroid the right way.
Visit these websites to learn more
Synthroid.com
Information on Synthroid, the Synthroid Delivers Program, and even more resources for patients.
SynthroidDelivers
Program.com
For patients ready to enroll in the Synthroid Delivers Program.
References: 1. Data on file. 200K+ patients on Synthroid in the Synthroid Delivers Program. AbbVie, Inc. July 2026. 2. Data on file. IQVIA Data and Analytics. AbbVie, Inc. January 2023.
Hypothyroidism
SYNTHROID® (levothyroxine sodium) tablets for oral use is an L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression
SYNTHROID is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism.
SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
US-SYNT-220356